期刊文献+

18β甘草次酸对17β羟基类固醇脱氢酶Ⅲ表达的抑制及诱导前列腺癌细胞LNCaP凋亡的研究 被引量:2

18β-glycyrrhetinic Acid Inhibit Human 17β-hydroxysteroid Dehydrogenase Type Ⅲ and Induce Cell Apoptosis via Activation of eIF2α in Prostate Cancer
下载PDF
导出
摘要 目的探讨18β甘草次酸(18β-GA)对17β羟基类固醇脱氢酶Ⅲ(17βHSD3)表达的抑制作用及诱导雄性激素依靠性前列腺癌细胞株LNCaP凋亡的作用机制。方法采用MTT法检测给予不同浓度18β-GA的LNCaP细胞的增殖率以确定其最佳作用浓度、时间及与剂量的依赖关系;采用Western blot检测真核启动因子2α(p-eIF2α)及活化转录因子4(ATF4)蛋白的表达;采用Real-time qPCR方法检测17βHSD3 mRNA的变化情况;用siRNA干扰eIF2αmRNA的表达从而确定eIF2α的作用。结果MTT结果显示:18β-GA浓度为8μmol/L时OD450 nm处吸光值明显减低,与对照组相比差异有统计学意义(P<0.05)。Westernblot结果显示:18β-GA对p-eIF2α及ATF4的表达具有促进作用。Real-time qPCR结果显示:18β-GA对17βHSD3 mRNA的转录具有抑制作用。结论 18β-GA通过激活eIF2α抑制17βHSD3的表达,并诱导LNCaP细胞株的凋亡,从而抑制肿瘤生长。 Objective To study the mechanism of 18β-GA induced 17β-HSD3 expression inhibition and cell apoptosis in androgen-dependence prostate cancer cell line LNCaP.Methods Cell proliferation rate of LNCaP cells exposed to different concentrations of 18β-GA was detected in order to determine the optimum concentration of the reagent and time and dose dependency;the expression of ATF4 and eIF2α was detected by Western blot;the level of 17βHSD3 mRNA was evaluated by Real-time qPCR;the function of eIF2α was determined by knock-down with siRNA.Results MTT assay showed that absorbance value at OD450nm was significantly reduced at the 18β-GA concentration of 8 μmol/L,and the difference was statistically significant(P 0.05);Western blot showed that 18β-GA promoted the expression of ATF4 and eIF2α;real-time qPCR results indicated that 18β-GA inhibited the transcription of 17βHSD3 mRNA via phosphorylation of eIF2α.Conclusion 18β-GA inhibited the expression of 17βHSD3 mRNA and induced the apoptosis in androgen-dependence of prostate cancer cell line LNCaP,resulting in suppressing tumor growth.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2012年第10期882-885,共4页 Journal of China Medical University
基金 辽宁省科技计划项目(2009225033)
关键词 18β甘草次酸 17β羟基类固醇脱氢酶Ⅲ EIF2Α 前列腺癌 18β-glycyrrhetinic acid 17β-hydroxysteroid dehydrogenase type Ⅲ eIF2α prostate cancer
  • 相关文献

参考文献13

  • 1Harada K, Kubo H,Abe J,et al. Discovery of potent and orally bioavailable 1713-hydroxysteroid dehydrogenase type 3 inhibitors J I. Bioorg Med Chem, 2012,20 (10) : 3242-3254.
  • 2毕泗成,徐秀红,邵强,杜林栋.米非司酮对雄激素非依赖性前列腺癌LNCaPC_(4-2)和PC3细胞的作用机制[J].首都医科大学学报,2004,25(2):250-252. 被引量:2
  • 3Ebeling P, Koivisto VA. Physiological importance of dehydroepiandros- terone[ J ]. Lancet, 1994,343 ( 8911 ) : 1479-1481.
  • 4Adams JB. Control of secretion and the function of C19-delta 5- steroids of the human adrenal gland [J]. Mol Cell Endoerinol, 1985, 41 (1):1-17.
  • 5Mindnich R, Moller G, Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases[ J ]. Mol Cell Endocrinol, 2004,218 ( 1-2 ) : 7-20.
  • 6Adamski J,Jakob FJ. A guide to 17beta-hydroxysteroid dehydroge- nases[ J ]. Mol Cell Endocrinol, 2001,171 ( 1-2): 1-4.
  • 7Mindnich R,Hrabe de Angelis M,Adamski J. Functional genome analysis indicates loss of 17beta-hydroxysteroid dehydrogenase type 2 enzyme in the zebrafish[J]. J Steroid Biochem ]Viol Biol,2007,103 ( 1 ) : 35-43.
  • 8Spires TE, Fink BE, Kick EK, et al. Identification of novel functional inhibitors of 17 beta-hydroxysteroid dehydrogenase type ( 17beta- HSD3 ) [J]. Prostate, 2005,65 (2) : 159-170.
  • 9Seher HI, Buchanan G, Gerald W, et al. Targeting the androgen re- ceptor:improving outcomes for castration-resistant prostate cancer [J]. Endocr Relat Cancer,2004,11 (3):459-476.
  • 10Roach M. Hormonal therapy and radiotherapy for localized prostate cancer:who,where and how long?[J]. J Uml,2003,170 (6 Pt 2): S35-S40.

二级参考文献4

  • 1Ragha D, Koczwara B. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. E ur J Cancer, 1997,33:566~574
  • 2Kuban D A, Shelhammer P F. Hemibody irradiation in advance d prostatic carcinoma. Urology Clin North Am, 1991,18(1):131~137
  • 3El Etraby M F, Yayun Liang. Induction of apoptosis by mife pristone and tamoxifen in human LNCaP prostate cancer cell culture. Prostate, 20 00,43:31~42
  • 4Lewis R W, Lewis J E. A preoperative plot clinical trial to study the effects of the antiprogestin,mifepristone in patients with op erable prostate cancer. Prostate, 1999,42:37~56

共引文献1

同被引文献34

引证文献2

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部